Episode

2025 Year in Review - Part 1

Podcast
Eyewire News: The Podcast
Published
Dec 24, 2025
Duration seconds
577
Processing state
not_requested
Canonical source
https://traffic.megaphone.fm/BMCL2456331568.mp3
Audio
https://traffic.megaphone.fm/BMCL2456331568.mp3
JSON
/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/2025-year-in-review-part-1
Markdown
/podcast/eyewire-news-the-podcast-7055536/2025-year-in-review-part-1.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/eyewire-news-the-podcast-7055536/episodes/2025-year-in-review-part-1/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/eyewire-news-the-podcast-7055536/2025-year-in-review-part-1.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

There were several advancements made during the first 6 months of 2025, including the first FDA approval for neurodegenerative disease MacTel; the approval of a first-of-its-kind drug for dry eye disease; advancements in premium IOLs; the approval of an excimer laser platform, and the launch of a new presbyopia drop. Learn more about your ad choices. Visit megaphone.fm/adchoices